A combination of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and anti-VEGF enhanced the anti-tumor efficacy to overcome the EGFR TKI resistance in lung cancer-induced mice [99]. The gene discussed is EGFR; the disease is neoplasm.